- Home
- ACRV vs VNRX Comparison
ACRV vs VNRX Comparison
Compare ACRV & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- VNRX
- Stock Information
- Founded
- ACRV 2018
- VNRX N/A
- Country
- ACRV United States
- VNRX United States
- Employees
- ACRV N/A
- VNRX N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ACRV Health Care
- VNRX Health Care
- Exchange
- ACRV Nasdaq
- VNRX Nasdaq
- Market Cap
- ACRV 42.5M
- VNRX 45.2M
- IPO Year
- ACRV 2022
- VNRX N/A
- Fundamental
- Price
- ACRV $1.81
- VNRX $0.49
- Analyst Decision
- ACRV Strong Buy
- VNRX Strong Buy
- Analyst Count
- ACRV 6
- VNRX 5
- Target Price
- ACRV $21.80
- VNRX $3.75
- AVG Volume (30 Days)
- ACRV 412.6K
- VNRX 310.7K
- Earning Date
- ACRV 05-13-2025
- VNRX 05-12-2025
- Dividend Yield
- ACRV N/A
- VNRX N/A
- EPS Growth
- ACRV N/A
- VNRX N/A
- EPS
- ACRV N/A
- VNRX N/A
- Revenue
- ACRV N/A
- VNRX $1,233,511.00
- Revenue This Year
- ACRV N/A
- VNRX $812.84
- Revenue Next Year
- ACRV N/A
- VNRX $162.93
- P/E Ratio
- ACRV N/A
- VNRX N/A
- Revenue Growth
- ACRV N/A
- VNRX 59.10
- 52 Week Low
- ACRV $1.30
- VNRX $0.42
- 52 Week High
- ACRV $11.51
- VNRX $1.02
- Technical
- Relative Strength Index (RSI)
- ACRV 34.69
- VNRX 42.51
- Support Level
- ACRV $1.30
- VNRX $0.45
- Resistance Level
- ACRV $2.19
- VNRX $0.54
- Average True Range (ATR)
- ACRV 0.32
- VNRX 0.07
- MACD
- ACRV 0.10
- VNRX -0.00
- Stochastic Oscillator
- ACRV 51.00
- VNRX 33.33
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.